Gilead Sciences Inc. has been in leadership limbo for five uncomfortable months; replacing a CEO and chairman combination that turned the company into a giant isn’t easy.
So the hiring on Monday of Roche Holding AG pharma head Daniel O’Day comes as a significant relief. It ends uncertainty, for sure. More important, O’Day is clearly qualified. He’s a veteran of one of the world’s most successful pharma firms and has deep expertise with cancer medicines, a priority for Gilead.